Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Heike Woehling
Observed names:
H Woehling,
H. Woehling,
H. Wöhling,
Heike Wöhling,
Woehling, Heike
Institution:
Hexal (Germany)
Observed institutions:
Novartis (Switzerland),
German Sport University Cologne,
Hexal (Germany),
Menarini Group (Germany),
Berlin-Chemie AG (Germany)
OpenAlex ID:
A5047430560
The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis
2017
·
C.E.M. Griffiths
, D. Thaçi
, et al.
·
British Journal of Dermatology
·
200
PDF
Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin*1
2004
·
S MUELLER
, Bernhard Uehleke
, et al.
·
Clinical Pharmacology & Therapeutics
·
146
Multiple switches between GP 2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study
2017
·
S. Gerdes
, D. Thaçi
, et al.
·
Journal of the European Academy of Dermatology and Venereology
·
84
PDF
Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden
2013
·
Carl-Erik Flodmark
, Katarina Lilja
, et al.
·
Biologics in Therapy
·
46
PDF
Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
2018
·
Marco Matucci-Cerinic
, Yannick Allanore
, et al.
·
RMD Open
·
45
PDF
Nebivolol and Metoprolol for Treating Migraine: An Advance on β ‐Blocker Treatment?
2007
·
Rudiger Schellenberg
, Albert Lichtenthal
, et al.
·
Headache The Journal of Head and Face Pain
·
45
GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes
2016
·
Oliver von Richter
, Andrej Skerjanec
, et al.
·
British Journal of Clinical Pharmacology
·
33
PDF
Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study
2011
·
Hanns-Martin Lorenz
, Wilhelm H Schmitt
, et al.
·
Arthritis Research & Therapy
·
17
PDF
Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System
2014
·
Nazia Rashid
, Paul Saenger
, et al.
·
Biologics in Therapy
·
14
PDF
Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age
2016
·
Hans-Peter Schwarz
, Mieczysław Walczak
, et al.
·
Advances in Therapy
·
9
PDF
Longitudinal assessment of the impact of multiple switches between a biosimilar and its reference product on efficacy parameters
2018
·
Johanna Mielke
, Heike Woehling
, et al.
·
Pharmaceutical Statistics
·
8
THU0145 Pharmacokinetics and Safety of GP2015, A Proposed Etanercept Biosimilar, and Etanercept Originator Product in Healthy Male Subjects: A Randomised Two-Way Crossover Study
2016
·
M. Afonso
, S. Sanguino Heinrich
, et al.
·
Annals of the Rheumatic Diseases
·
8
002 Switching treatments of etanercept biosimilar GP2015 with originator product does not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis
2017
·
C.E. Griffiths
, K. Reich
, et al.
·
Journal of Investigative Dermatology
·
6
Assessing switchability for biosimilar products: modelling approaches applied to children's growth
2015
·
Rossella Belleli
, Roland Fisch
, et al.
·
Pharmaceutical Statistics
·
6
State‐of‐the‐art immunogenicity evaluation in phase 3 confirmatory study ( EGALITY ) with etanercept biosimilar GP 2015
2017
·
J. Poetzl
, I. Arlt
, et al.
·
Journal of the European Academy of Dermatology and Venereology
·
5
THU0144 Pharmacokinetics and Safety of GP2015, A Proposed Etanercept Biosimilar, Administered Subcutaneously by An Autoinjector or Prefilled Syringe in Healthy Male Subjects
2016
·
M. Afonso
, D. Kollins
, et al.
·
Annals of the Rheumatic Diseases
·
3
Type I Error Inflation of Blinded Sample Size Re-Estimation in Equivalence Testing
2020
·
Ekkehard Glimm
, Lillian Yau
, et al.
·
Statistics in Biopharmaceutical Research
·
1
PDF
Type I Error Inflation of Blinded Sample Size Re-Estimation in Equivalence Testing
2020
·
Glimm, Ekkehard
, Yau, Lillian
, et al.
·
Figshare
A Randomized, Double-Blind, Multicenter Study to Compare the Efficacy, Safety, and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Originator Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
2017
·
Andrew Blauvelt
, Joseph F Fowler, Jr.
, et al.
·
SKIN The Journal of Cutaneous Medicine
PDF
018–Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study In An Integrated Healthcare System
2015
·
Maryann Olsen
, Nazia Rashid
, et al.
·
Journal of Pediatric Nursing
PDF
Erratum to: Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System
2014
·
Nazia Rashid
, Paul Saenger
, et al.
·
Biologics in Therapy
PDF
Randomised placebo‐controlled clinical study (phase IV) on muscle‐relaxing and muscle pain‐relieving effects of a mixture of etherial oils (Dolo‐cyl Öl)
2005
·
B Uehleke
, F Boldt
, et al.
·
Focus on Alternative and Complementary Therapies
A pilot study by letter with hydrotherapy for polyneuropathic complaints
2004
·
B Uehleke
, J Moennich
, et al.
·
Focus on Alternative and Complementary Therapies
Show more works
View as search
Works count:
27
Citation count:
676
H-index:
9
I10-index:
9
Year
Topic
Type